The
disturbing increase in the number of bacterial pathogens that are
resistant to multiple, or sometimes all, current antibiotics highlights
the desperate need to pursue the discovery and development of novel
classes of antibacterials. The wealth of knowledge available about
the bacterial cell division machinery has aided target-driven approaches
to identify new inhibitor compounds. The main division target being
pursued is the highly conserved and essential protein FtsZ. Despite
very active research on FtsZ inhibitors for several years, this protein
is not yet targeted by any commercial antibiotic. Here, we discuss
the suitability of FtsZ as an antibacterial target for drug development
and review progress achieved in this area. We use hindsight to highlight
the gaps that have slowed progress in FtsZ inhibitor development and
to suggest guidelines for concluding that FtsZ is actually the target
of these molecules, a key missing link in several studies. In moving
forward, a multidisciplinary, communicative, and collaborative process,
with sharing of research expertise, is critical if we are to succeed.